#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mantle cell lymphoma stage III Cardiac failure acute Anti-myelin-associated glycoprotein antibodies positive Hypomagnesaemia Astrocytoma Medulloblastoma Hereditary angioedema with C1 esterase inhibitor deficiency Neurotrophic keratopathy Glioblastoma multiforme Autologous haematopoietic stem cell transplant Pulmonary fibrosis Meningococcal immunisation Cytokine release syndrome Raynaud's phenomenon Fragile X syndrome More trials…

    Learn about Rare Diseases

    Hereditary hypophosphataemic rickets – Trials in Disease Anaplastic thyroid cancer – Life with Disease Familial amyotrophic lateral sclerosis Hereditary angioedema – Basic Information Alveolar rhabdomyosarcoma Lymphangioma – Diagnostics Langerhans cell sarcoma Pemphigus – Life with Disease Pemphigus – Trials in Disease Ocular melanoma – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Mifepristone Crisantaspase Carbidopa Selinexor Tiapride Elenestinib Phosphate Atl001 Levothyroxine Sodium Fosphenytoin Sodium Tislelizumab Utreglutide Pbf-999 Mepolizumab Avelumab Degarelix Acetate Livmoniplimab Amlodipine Palonosetron Hydrochloride Briquilimab NERANDOMILAST More therapies…

    Learn about Your Condition

    Metastases to lymph nodes Hypopituitarism Tricuspid valve disease Hypothyroidism Liposarcoma recurrent Vulval cancer recurrent Uterine leiomyosarcoma Bacterial prostatitis Diabetic nephropathy Coronary artery disease Procedural haemorrhage Testicular germ cell tumour Deafness Hepatotoxicity Metastases to peritoneum More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Bladder cancer

  • Study on Avelumab for Patients with Advanced Urothelial Cancer After Initial Chemotherapy

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    • Bladder cancer
    Investigated Drugs:
    • Avelumab
    The Netherlands

  • Study of Atezolizumab with BCG Treatment for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Previously Received BCG

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Atezolizumab
    Belgium France Spain

  • Study on Mycobacterium Bovis Bacillus Calmette-Guérin for High-risk Non-muscle Invasive Bladder Cancer Patients

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Bladder cancer recurrent
    • Bladder cancer
    Spain

  • Study on UGN-102 (Mitomycin) for Treating Low Grade Non-Muscle Invasive Bladder Cancer in Patients at Intermediate Risk of Recurrence

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Mitomycin
    Austria Bulgaria Estonia Latvia Lithuania Poland +1

  • Study of Sasanlimab Treatment as a Bladder-Sparing Strategy in Patients with Muscle Invasive Bladder Cancer

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Anti-Pdcd1 Igg4 Humanised Monoclonal Antibody
    • Sasanlimab
    Spain

  • Study on Reduced Dose Intensity of Pembrolizumab and Drug Combination for Patients with Advanced or Metastatic Cancer Responding to Standard Immunotherapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Lung neoplasm malignant
    • Neuroendocrine carcinoma of the skin
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Avelumab
    • Atezolizumab
    • Cemiplimab
    France
Previous Page
1 2 3 4 5 6 … 9
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!